Details for New Drug Application (NDA): 211040
✉ Email this page to a colleague
NDA 211040 describes SIROLIMUS, which is a drug marketed by Amneal, Apotex, Hetero Labs Ltd V, MSN, Novitium Pharma, Torrent, Alkem Labs Ltd, Dr Reddys, Glenmark Pharms Ltd, and Zydus Pharms, and is included in ten NDAs. It is available from fourteen suppliers. Additional details are available on the SIROLIMUS profile page.
The generic ingredient in SIROLIMUS is sirolimus. There are twenty-one drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the sirolimus profile page.
The generic ingredient in SIROLIMUS is sirolimus. There are twenty-one drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the sirolimus profile page.
Summary for 211040
| Tradename: | SIROLIMUS |
| Applicant: | Novitium Pharma |
| Ingredient: | sirolimus |
| Patents: | 0 |
Pharmacology for NDA: 211040
| Mechanism of Action | Protein Kinase Inhibitors mTOR Inhibitors |
| Physiological Effect | Decreased Immunologic Activity |
Medical Subject Heading (MeSH) Categories for 211040
Suppliers and Packaging for NDA: 211040
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SIROLIMUS | sirolimus | SOLUTION;ORAL | 211040 | ANDA | VistaPharm, LLC | 66689-347 | 66689-347-02 | 1 CARTON in 1 KIT (66689-347-02) / 1 BOTTLE in 1 CARTON / 60 mL in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 1MG/ML | ||||
| Approval Date: | Jan 28, 2019 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
